Form D · Biotechnology
Paragon Therapeutics, Inc.
Philadelphia, PA · CIK 0001861055
Offering snapshot reported May 10, 2021 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 10, 2021 | Initial | $10,000,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-398700
Source: Form D, filed May 10, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Harwin | Director, Promoter |
| Evan Thompson | Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Fairmount Funds Management, Llc 2001 Market Street, Suite 2500
Philadelphia, PA, 19103
Philadelphia, PA, 19103